Biomerieux Q3 Sales Up 7 Percent

Oct 20, 2016

NEW YORK (GenomeWeb) – Biomerieux reported today that its third quarter revenues rose 7 percent from Q3 2015, including a 46 percent jump in molecular biology sales.

For the quarter ended Sept. 30, the company reported total revenues of €510.8 million ($557.3 million) from €478.3 million a year ago.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Biomerieux Q3 Sales Up 7 Percent

To read the full story....

Breaking News

Vela Diagnostics Receives Second FDA Emergency Use Authorization for SARS-CoV-2 Molecular Test

Centogene Reports 13 Percent Decline in Q2 Revenues

Becton Dickinson Submits Premarket Approval Supplement to FDA for HPV Assay

BioReference Settles False Claims, Kickback Allegations for $11.5M

Quest, Walmart Teaming Up to Deliver SARS-CoV-2 Home Sampling Kits Via Drone

UBS Downgrades Illumina to Neutral; Expresses Doubts About Grail Deal

Featured White Papers

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

What's Popular?

FDA Grants Emergency Use Authorization for GK Pharmaceuticals Coronavirus Test

FDA Publishes First Batch of SARS-CoV-2 MDx Limit of Detection Comparison Results

Becton Dickinson Submits Premarket Approval Supplement to FDA for HPV Assay

Promega to Develop MSI Assay as CDx for Incyte Endometrial Cancer Drug

Centogene Reports 13 Percent Decline in Q2 Revenues

Sponsorships